Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnnexonANNX -0.60%34 3-Year EPS without NRI Growth Rate is 19.80% as of Jun. 2026, which is at its 10-year median of 19.80. GuruFocus rates ANNX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,159 Biotechnology companies, Annexon ranks better than 54.7% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 19.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 24.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Annexon was 33.30% per year. The lowest was -28.20% per year. And the median was 19.80% per year.
Annexon (NAS:ANNX) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Annexon 3-Year EPS without NRI Growth Rate Related Terms
ANNX vs DSGN, GERN, ARDX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Annexon's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Annexon's 3-Year EPS without NRI Growth Rate falls into.
Annexon 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 19.80% mean?
Annexon (ANNX) has a 3-Year EPS without NRI Growth Rate of 19.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Annexon and its competitors. This is near median its historical median of 19.80. According to the industry distribution chart, Annexon ranks #525 out of 1159 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Annexon's 3-Year EPS without NRI Growth Rate too high?
Annexon's current 3-Year EPS without NRI Growth Rate of 19.80% is near median its 10-year median of 19.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Annexon's value of 19.80% is 22.2% above this industry median. Based on the distribution chart, Annexon ranks #525 out of 1159 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annexon has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Annexon's 3-Year EPS without NRI Growth Rate compare to DSGN and GERN?
According to the Biotechnology industry distribution chart, Annexon ranks #525 out of 1159 companies for 3-Year EPS without NRI Growth Rate. This puts Annexon in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Annexon's value of 19.80% is 22.2% above this benchmark. While the company's 10-year median is 19.80 vs. the industry median of 16.20, Annexon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,159 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annexon's current 3-Year EPS without NRI Growth Rate of 19.80% is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Annexon and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annexon's current 3-Year EPS without NRI Growth Rate is 19.80%, which is near median its own 10-year median of 19.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexon stock overvalued right now?
Annexon (ANNX) has a current 3-Year EPS without NRI Growth Rate of 19.80%. The current 3-Year EPS without NRI Growth Rate is 19.80%, which is near median its 10-year median of 19.80 and 22.2% above the Biotechnology industry median of 16.20. Annexon's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Annexon (ANNX), the current 3-Year EPS without NRI Growth Rate is 19.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
34GF Score
Get the complete analysis for ANNX
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANNX has been successfully added to your 
